KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2016 - 2025)

Acadia Pharmaceuticals has reported Other Accumulated Expenses over the past 15 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $5.6 million for Q4 2025, up 64.81% from a year ago — trailing twelve months through Dec 2025 was $5.6 million (up 64.81% YoY), and the annual figure for FY2025 was $5.6 million, up 64.81%.
  • Other Accumulated Expenses for Q4 2025 was $5.6 million at Acadia Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ACAD hit a ceiling of $13.7 million in Q1 2024 and a floor of $986000.0 in Q2 2022.
  • Median Other Accumulated Expenses over the past 5 years was $5.3 million (2025), compared with a mean of $6.3 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 777.84% in 2023 and later crashed 69.31% in 2024.
  • Acadia Pharmaceuticals' Other Accumulated Expenses stood at $2.7 million in 2021, then increased by 0.82% to $2.7 million in 2022, then surged by 307.53% to $11.0 million in 2023, then crashed by 69.31% to $3.4 million in 2024, then soared by 64.81% to $5.6 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $5.6 million (Q4 2025), $5.0 million (Q3 2025), and $13.4 million (Q2 2025) per Business Quant data.